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Summary
We previously reported that p97/p47-assisted mem-
brane fusion is important for the reassembly of organ-
elles at theendofmitosis, butnot for theirmaintenance
during interphase. We have now identified a p97 adap-
tor protein, p37, which forms a complex with p97 in the
cytosol and localizes to theGolgi andER. siRNAexper-
iments revealed that p37 is required for Golgi and ER
biogenesis. Injection of anti-p37 antibodies into cells
at different cell cycle stages showed that p37 plays
an important role in both Golgi and ER maintenance
during interphase as well as in their reassembly at
the end of mitosis. In an in vitro Golgi reassembly as-
say, the p97/p37 complex has membrane fusion activ-
ity. In contrast to the p97/p47 pathway, this pathway
requires p115-GM130 tethering and SNARE GS15, but
not syntaxin5. Interestingly, although VCIP135 is also
required, its deubiquitinating activity is unnecessary
for p97/p37-mediated activities.
Introduction
The Golgi apparatus occupies a central position in the
secretory pathway, where it receives the entire output
of de novo-synthesized proteins from the ER, and func-
tions to distil, posttranslationally process, and sort
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7 These authors contributed equally to this work.cargo to their ultimate destinations. The Golgi is frag-
mented into many small vesicles and short tubules dur-
ing mitosis and is rapidly reassembled from such frag-
ments within each daughter cell (Lucocq et al., 1989).
Experiments conducted with an in vitro function assay,
which mimics Golgi reassembly at the end of mitosis,
showed that reassembly from membrane fragments re-
quires at least two ATPases: N-ethylmaleimide-sensitive
factor (NSF) and p97 (also known as VCP) (Rabouille
et al., 1995a). The role of NSF has been well character-
ized, while much less is known about the mechanism
of action of p97. Two cofactors have so far been identi-
fied, namely, p47 and VCIP135 (VCP[p97]/p47 complex-
interacting protein, p135). p47 forms a tight complex
with p97, which is essential for in vitro Golgi reassembly
(Kondo et al., 1997). The SNARE protein (soluble NSF at-
tachment protein [SNAP] receptor) syntaxin5 is a recep-
tor in Golgi membranes for the p97/p47 complex, and
p47 mediates the binding of p97 to syntaxin5 (Rabouille
et al., 1998). VCIP135 binds to the p97/p47/SNARE com-
plex and dissociates it via p97-catalyzed ATP hydrolysis
(Uchiyama et al., 2002). Recently, VCIP135 has been re-
ported to possess deubiquitinating activity (Wang et al.,
2004).
We previously showed that the injection of anti-p47
antibodies into mitotic cells inhibited the reassembly of
Golgi and ER in daughter cells (Uchiyama et al., 2002).
We also reported that mitotic phosphorylation of p47 is
important for Golgi disassembly at the onset of mitosis,
as microinjection of p47(S140A), which is unable to be
phosphorylated, allows cells to maintain Golgi stacks
during mitosis. Consequently, the membrane fusion ac-
tivity assisted by the p97/p47 complex is thought to be
important for the reassembly of organelles at the end of
mitosis (Uchiyama et al., 2003). However, p47 has two
nuclear localization signals and mainly localizes to the
nucleus in interphase cells. The injection of highly con-
centrated anti-p47 antibodies into the cytoplasm of
interphase cells does not result in any morphological
changes. It is therefore likely that p97/p47-assisted
membrane fusion is less critical during interphase than
at the end of mitosis (Uchiyama et al., 2003). These ob-
servations pose the question: Does p97 have another
pathway besides the p97/p47 pathway for the mainte-
nance of organelles during interphase? Alternatively, is
p97-assisted membrane fusion not necessary for the
maintenance of organelles in interphase cells? Dalal
et al. (2004) indeed reported that no morphological
change was observed in Golgi when a p97 mutant lack-
ing ATPase activity was expressed in culture cells. How-
ever, it is possible that the inactivation of the endoge-
nous p97 might be insufficient to inhibit p97-assisted
membrane fusion in their study.
Here, we report a novel membrane fusion pathway that
requires the p97/p37 complex. p37 forms a tight com-
plex with p97 in the cytosol. This adaptor protein of
p97 localizes to the Golgi and ER and is required for their
maintenance during interphase as well as for their reas-
sembly at the end of mitosis. The p97/p37 complex
also shows membrane fusion activity in an in vitro Golgi
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804Figure 1. p37 Is Similar to p47
(A) Amino acid sequence alignment of p37 and p47. The C-terminal p47 UBX domain (shaded in light blue) is highly homologous to the predicted
p37 UBX domain (w63% sequence identity). The SEP domain (shaded in yellow) is also found in p37 (w72% sequence identity). The p47 phos-
phorylation site at serine-140 is shaded in green, and the two p47 nuclear localization signals missing in p37 are shaded in red. p37 does not
contain a defined N-terminal UBA domain; hydrophobic core residues in the p47 UBA domain (shaded in blue) are not well conserved, and
some residues are missing. Identical residues between the two proteins are marked with asterisks.
(B) The amount of p37 in various tissues. Rat tissue proteins were extracted from 0.2 mg (wet weight) of tissue in sample buffer and fractionated
by SDS-PAGE. Blots were probed with polyclonal antibodies to p97, p47, and p37.reassembly assay; however, this activity has several
important mechanistic differences compared to that of
p97/p47-assisted membrane fusion.
Results
p37 Forms a Complex with p97
Since p47 mainly localizes to the nucleus at interphase,
p97/p47-assisted membrane fusion is not critical for
the maintenance of Golgi during interphase (Uchiyama
et al., 2003). In contrast to the subcellular distribution
of p47, p97 localizes to both the nucleus and the cyto-
plasm at interphase. Hence, it is plausible that p97
may have another adaptor, which localizes to the cyto-
plasm during interphase, for the maintenance of Golgi
and ER.
Furthermore, the expression of such a cofactor might
be expected to be higher in nonproliferating tissues,
such as brain, than in proliferating tissues. We therefore
used a brain cDNA library to perform a yeast two-hybrid
screen, and we identified one clone that had a predicted
peptide sequence similar to that of p47; its predictedmolecular weight was 37 kDa, and, hence, we called it
‘‘p37’’ (Figure 1A). The UBX and SEP domains, which
are important for p47 binding to p97, are highly homolo-
gous between p37 and p47. Interestingly, the two nu-
clear localization signals present in p47 are absent in
p37. p37 doesn’t contain a defined UBA domain, which
is important for the binding to ubiquitin; key hydropho-
bic core residues in the p47 UBA domain (Figure 1A,
shaded in blue) are not well conserved in p37, and
some residues are missing.
As shown in Figure 1B, western blotting confirmed the
existence of p37 in brain, liver, kidney, spleen, testis,
lung, and heart. p37 was present in all tissues studied
and was especially abundant in brain.
Since p37 has both the UBX and SEP domains, we
would expect p37 to bind to p97. We tested this by using
several biochemical techniques. Figure 2A shows the
results of coimmunoprecipitation from rat brain cytosol.
Anti-p37 antibodies pulled down a protein of 97 kDa
(left), which was shown to be p97 by western blotting
(right top). However, p47 could not be detected in the
precipitates (right middle). These data suggest that
p97/p37 Is Required for Golgi and ER Biogenesis
805Figure 2. p37 Forms a Complex with p97
(A) Rat brain cytosol was incubated with anti-p37 antibodies. The immunoprecipitates were fractionated by SDS-PAGE, followed by staining with
Coomassie blue (CBB, left panel) and western blotting with antibodies to p97, p47, and p37 (WB, right panels).
(B) Rat brain cytosol was size fractionated by gel filtration, and the fractions were assayed by western blotting.
(C) His-tagged p37 was incubated with an excess amount of p97 in a buffer containing 0.15 M KCl and 0.1% Triton X-100 on ice, then precipitated
by anti-His tag antibodies. p37 and bound p97 were separated by SDS-PAGE and stained with CBB.
(D) GST-tagged p97 (0.3 mg) was incubated with the indicated His-tagged proteins (p37, 0.3 mg; p47, 0.4, 2, or 6 mg; Ufd1, 0.3, 1.5, or 4.5 mg; Npl4,
0.6, 3, or 9 mg; SVIP, 0.15, 0.75, or 2.25 mg) in a buffer containing 0.15 M KCl, 0.1% Triton X-100, and 5 g/l trypsin inhibitor on ice, then isolated on
glutathione beads; bound proteins were fractionated by SDS-PAGE. The blots were probed with antibodies to p97 and His tag.
(E) GST-tagged ubiquitin (Ub-GST, 0.4 mg) was incubated with the indicated proteins (p97, 0.1 mg; p47, 0.05 mg; p37, 0.05 mg), then isolated on
glutathione beads;bound proteins fractionated by SDS-PAGE. The blots were probed with antibodies to p97, p47, p37, and Ub.p37 can form a stable complex with p97 in the cytosol,
and that p47 is not part of this complex. As presented
in Figure 2B, fractionation of the cytosol by gel filtration
showed that p37 mainly distributed to the p97-contain-
ing fractions. These results strongly indicate that p37
exists mainly in the form of a p97/p37 complex in the cy-
tosol. We next performed binding experiments with pu-
rified recombinant proteins. An excess amount of p97was incubated with His-tagged p37. p37 and bound
p97 were immunoprecipitated with anti-His antibodies
and were separated by SDS-PAGE, followed by CBB
staining (Figure 2C). p37 and p97 clearly formed a com-
plex, and the ratio of p97 to p37 was estimated as 2:1
(mol:mol) from the densities of the bands.
The next question was whether this p97/p37 complex
is distinct from known p97-containing complexes. To
Developmental Cell
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which are shown in Figure 2D. p37 and GST-tagged
p97 were incubated in the absence or presence of the
known p97 adaptors: p47, Ufd1/Npl4, and SVIP (Kondo
et al., 1997; Meyer et al., 2000; Nagahama et al., 2003).
We found that p47, Ufd1/Npl4, and SVIP all inhibited
the binding of p37 to p97 (p47, lanes 7–8; Ufd1/Npl4,
lanes 9–10; SVIP, lanes 11–12), indicating that p37 is
not a constituent of the p97/p47, p97/Ufd1/Npl4, or
p97/SVIP complexes. Given that we observed no bands
other than p97 and p37 in the coimmunoprecipitation ex-
periments (Figure 2A, left), we concluded that p37 forms
a novel, to our knowledge, stable complex with p97.
p47 has a UBA domain and is reported to bind to ubiq-
uitin in the presence of p97 (Meyer et al., 2002). In con-
trast, protein structure analysis including fold recogni-
tion predicts that p37 does not contain a defined UBA
domain (Figure 1A), suggesting that p37 does not bind
ubiquitin. To confirm this, we investigated ubiquitin
binding to p37 (Figure 2E). For comparison, p47 bound
ubiquitin in the presence of p97 (lane 4), while p37 did
not bind ubiquitin in either the presence or absence of
p97 (lanes 5–6) under the same experimental conditions.
p37 Is Important for the Biogenesis
of the Golgi and ER In Vivo
The subcellular distribution of p37 was determined by
immunofluorescence microscopy with PFA fixation.
p37 existed both in the cytoplasm and nucleus (Fig-
ure 3A, left), whereas p47 mainly localized to the nucleus
(middle). This is consistent with the lack of a defined
nuclear localization signal motif in p37 (Figure 1A). We
next clarified the localization of membrane-bound p37
by using methanol fixation. As shown in Figures 3B
and 3C, double immunofluorescence staining of p37
with either GM130, a Golgi marker, or protein disulfide
isomerase (PDI), an ER marker, showed the localization
of p37 to both the Golgi and ER. Given the similarity of
p37 to p47 (Figure 1A), we wanted to test whether p37,
like p47, plays a role in the biogenesis of the Golgi and
ER (Uchiyama et al., 2002).
We first carried out p37-knockdown experiments by
using siRNA (Figures 4A–4C). Two distinct p37 siRNA
duplexes, specific for the nucleotide sequence of hu-
man p37, were used in HeLa cells. In p37 siRNA-treated
cells, p37 was undetectable by immunofluorescence
staining (Figure 4A, [e] and [f]). Western blotting also
showed that both p37 siRNA duplexes decreased p37
levels to <5% of its original level (Figure S1A; see the
Supplemental Data available with this article online). In
p37-depleted cells, the Golgi still localized to a perinu-
clear region (Figure 4A, [b] and [c]). The ultrastructures
of the Golgi apparatus were further investigated by elec-
tron microscopy (Figures 4B and 4C). In p37-depleted
cells, the typical big stacks of Golgi were rarely ob-
served, and large-scale vesiculation was present (Fig-
ure 4B, top right and bottom panels). Membrane profiles
in the Golgi area were calculated, and the results are
shown in Figure 4C. Both p37 siRNAs significantly de-
creased the percentage of membranes in Golgi cister-
nae, while they increased the percentage of tubules
and vesicles within the Golgi area, compared with
mock control. These results strongly suggest that p37
is important for the biogenesis of Golgi.We have shown that p37 exists in the cytoplasm dur-
ing interphase (Figure 3), but does p37 function in the
maintenance of Golgi during interphase? To study this,
we injected anti-p37 antibodies into the cytoplasm of
interphase cells and investigated the ultrastructures of
their Golgi by electron microscopy. The cells that had
passed through mitosis were excluded in order to study
only interphase cells. Figure 4D shows the quantitative
results. The injection of anti-p37 antibodies significantly
decreased the percentage of membranes in Golgi cister-
nae, and it significantly increased the percentage of
tubules and vesicles, compared with the injection of
random IgG (control). These effects were not observed
when quenched antibodies were injected. Next, we in-
jected the same antibodies into mitotic cells and inves-
tigated the effects on Golgi reassembly at the end of mi-
tosis. Cells at prophase (or early prometaphase) were
injected with anti-p37 antibodies and were fixed after
they entered interphase. The injection of the antibodies
had no effect on cell cycle progression. As shown in
Figure 4E, in antibody-injected daughter cells, the per-
centage of cisternae significantly decreased in the Golgi
area, although this decrease was smaller compared with
that observed for injected interphase cells. The percent-
age of tubules in the Golgi area was significantly in-
creased by the injection of anti-p37 antibodies. These
results strongly suggest that p37 plays an important
role in Golgi maintenance during interphase as well as
in its reassembly at the end of mitosis.
We next investigated the role of p37 on the biogenesis
of ER. Figure 5A shows ER structures in mock- and p37
siRNA-treated cells. Two distinct p37 siRNA duplexes
suppressed the p37 level to <5% of its original level
(Figure S1B). Both p37 siRNA duplexes caused the for-
mation of a large, meshed ER network (the middle and
right panels of Figure 5A), which was not observed in
mock-treated cells (the left panel in Figure 5A). To quan-
tify the degree of ER network formation, the number of
three-way junctions was counted in living cells by using
confocal microscopy, and the results are presented in
Figure 5B. The number of three-way junctions was sig-
nificantly decreased by p37 siRNA treatments. We also
injected anti-p37 antibodies into cells at different cell cy-
cle stages. As presented in Figures 5C and 5D, the injec-
tion of anti-p37 antibodies into interphase and mitotic
cells significantly decreased the number of ER three-
way junctions to w35% and w60% of control (random
IgG injection), respectively. These changes disappeared
by quenching the antibodies. All of these results indicate
that p37 functions in ER network formation.
The importance of p37 in the maintenance of the ER
and Golgi suggests that p37 has possible functions in
membrane trafficking from the ER to the plasma mem-
brane. To test this, we depleted p37 in living cells and
studied the transport of VSV-G, a reporter protein for
membrane transport in secretory pathways. A thermor-
eversible folding mutant of VSV-G fused to GFP at its C
terminus (ts045-VSV-G-GFP). This mutant misfolds and
is retained in the ER at 39.5C; however, upon a temper-
ature shift to 32C, it can fold and be transported to the
Golgi and, subsequently, to the plasma membrane. The
results are presented in Figures 6A and 6B. In mock-
transfected cells, ts045-VSV-G-GFP was transported
to the Golgi at the 20 min time point (Figure 6A, upper
p97/p37 Is Required for Golgi and ER Biogenesis
807Figure 3. p37 Localizes to the Golgi and ER during Interphase
(A) The distribution of p37, p47, and p97. NRK cells were fixed with paraformaldehyde, permeabilized with Triton X-100, stained with polyclonal
antibodies to p37, p47, and p97, and observed by confocal microscopy. The scale bar is 10 mm.
(B) Double immunofluorescence staining of p37 and GM130, a Golgi marker, shows that p37 localizes to the Golgi. NRK cells were fixed with
methanol at 220C for 4 min, stained with antibodies, and observed by confocal microscopy. The scale bar is 10 mm.
(C) Double immunofluorescence staining of p37 and PDI, an ER marker, shows that p37 localizes to the ER. CHO cells were fixed with methanol
at 220C for 4 min, stained with antibodies, and observed by confocal microscopy. The scale bar is 2 mm.middle) and to the plasma membrane at the 60 min time
point (upper right). In p37-depleted cells, ts045-VSV-G-
GFP was transported to the Golgi at the 20 min time
point (lower middle) and still remained in the Golgi at
the 60 min time point (lower right). To quantify these ob-
servations, more than 400 cells per time point were
counted, and the calculated results are presented in Fig-
ure 7B. In the p37-depleted cells, there was no change in
the ER-to-Golgi transport of ts045-VSV-G-GFP, but its
transport through the Golgi was delayed (right panel,
red line). The delay might be explained by the disruptionof Golgi structures caused by p37 siRNA treatment.
There still remain some possibilities that p37 may also
play a role in the transport of vesicles from the Golgi to
the plasma membrane.
Since p97 is reported to be involved in ER-associated
degradation (ERAD) as well as in membrane fusion (Ye
et al., 2001), we tested whether the depletion of p37
had some effects on ERAD. The turnover of a model
ERAD substrate, DF508CFTR, was investigated to esti-
mate ERAD activity. As presented in Figure 6C, there
was no difference in DF508CFTR turnover between
Developmental Cell
808Figure 4. p37 Is Essential for the Biogenesis
of the Golgi In Vivo
(A) HeLa cells were either mock transfected
with water or transfected with two distinct
siRNA duplexes specific to p37. The cells
were incubated for 48 hr and then fixed. Since
the transfection efficiency wasw90%, espe-
cially in these images, untransfected cells
(asterisk [e] and [f]) were cocultured 24 hr af-
ter transfection in order to set a control. Golgi
(green, [a]–[c]), p37 (red, [d]–[f]), and chroma-
tin (blue, [d]–[f]) were stained by monoclonal
anti-GalT antibodies, polyclonal anti-p37
antibodies, and DAPI, respectively. The scale
bar is 10 mm.
(B) Representative EM images of Golgi in ei-
ther mock- or p37 siRNA-treated HeLa cells.
The scale bar is 0.5 mm.
(C) Golgi membranes in either mock- or p37
siRNA-treated HeLa cells were classified into
cisternae, vesicles, and tubules and were
counted as previously described (Shorter
and Warren, 1999). Means 6 SD (n = 8). An
asterisk indicates a significant difference at
p < 0.05 compared with mock (Bonferroni
method).
(D) NRK cells at interphase were injected with
anti-p37 antibodies, incubated for 4 hr, and
then fixed. The cells that entered mitosis
were removed every 1.5–2 hr during the incu-
bation in order to confirm that the remaining
cells had never passed through mitosis. Golgi
membranes in injected cells were classified
and counted. Means6 SD (n = 7). An asterisk
indicates a significant difference at p < 0.05
compared with random IgG (control).
(E) NRK cells at prophase (or early prometa-
phase) were injected with anti-p37 antibodies
and fixed after they exited mitosis. Golgi
membranes in the daughter cells were classi-
fied and counted. Means 6 SD (n = 8–9). An
asterisk indicates a significant difference at
p < 0.05 compared with random IgG.mock- and p37-depleted cells, indicating that p37 is not
involved in ERAD.
The p97/p37 Complex Shows Membrane Fusion
Activity
To clarify the molecular function of p37 in Golgi biogen-
esis, we used an in vitro Golgi reassembly assay (Ra-
bouille et al., 1995b). As shown in Figure 7A, anti-p37 an-
tibodies partially inhibited cisternal regrowth caused by
the addition of cytosol, which was enhanced by the ad-
dition of antibodies to p37 and p47 together. This result
suggested a possible role for p37 in membrane fusion.We tested this possibility by using purified proteins in-
stead of cytosol; the results are shown in Figure 7B.
There was little cisternal regrowth after incubation with
either p97 or p37 alone. The p97/p37 complex, however,
caused cisternal regrowth, and its fusion activity was in-
creased by the addition of p115 to almost the same level
as that of the p97/p47 complex. The cisternal regrowth
caused by p97/p37 and p115 was inhibited by the addi-
tion of anti-p37 antibodies, but not by anti-p47 anti-
bodies. Accordingly, the p97/p37 complex and p115
causes membrane fusion without the assistance of
p47. Figure 7C shows the effect of varying the ratio of
p97/p37 Is Required for Golgi and ER Biogenesis
809Figure 5. p37 Is Essential for the Biogenesis
of the ER In Vivo
(A) CHO-K1 cells expressing GFP-tagged
HSP47 were transfected with either mock or
two distinct siRNA duplexes specific to p37.
After incubation for 48 hr, ER structures
were observed in living cells without fixation
by confocal microscopy. Representative im-
ages of the ER after the transfection are
shown. N; nucleus. The scale bar is 5 mm.
(B) The numbers of ER three-way junctions in
either mock- or p37 siRNA-treated cells were
counted by using confocal microscopy as a
parameter of ER network formation. Means6
SD (n = 6–7). An asterisk indicates a signifi-
cant difference at p < 0.05 compared with
mock (Bonferroni method).
(C) The cells at interphase were injected with
anti-p37 antibodies and incubated for 4 hr.
The cells that entered mitosis were removed
every 1.5–2 hr during the incubation. After
the incubation, the number of three-way junc-
tions in ER network was counted. Means 6
SD (n = 7–8). An asterisk indicates a signifi-
cant difference at p < 0.05 compared with
random IgG (control).
(D) The cells at prophase (or early prometa-
phase) were injected with anti-p37 anti-
bodies. After they exited mitosis, the number
of ER three-way junctions was counted.
Means 6 SD (n = 8–9). An asterisk indicates
a significant difference at p < 0.05 compared
with random IgG.p37 to p97 on cisternal regrowth. Maximal regrowth oc-
curred at 0.5 mol p37:1 mol p97, consistent with the pro-
posed stoichiometry of the p97/p37 complex, namely,
2:1 (Figure 2C). It is likely that three molecules of p37
bind to a hexamer of p97.
It is reported that p115 binds to GM130 and functions
as a tethering system in NSF-assisted Golgi reassembly
(Nakamura et al., 1997). In contrast, the p97/p47 pathway
does not require p115 (Rabouille et al., 1995a). We inves-
tigated, by using antibodies to p115 and GM130, whether
p115 and GM130 are involved in p97/p37-dependent
Golgi reassembly. As shown in Figure 7D, each antibody
strongly inhibited p97/p37-dependent cisternal re-
growth, but they had no effect on p97/p47-dependent re-
growth. These results indicate that the p97/p37 pathway
is distinct from the p97/p47 pathway requiring the pres-
ence of the p115-GM130 tethering system.
We next investigated whether VCIP135, an essential
cofactor for p97/p47-assisted membrane fusion, is
involved in the p97/p37 pathway (Figure 7E). Anti-
VCIP135 antibodies inhibited cisternal regrowth caused
by p97/p37, and the inhibition was rescued by quench-
ing the antibodies with a VCIP135 fragment. These re-
sults suggest that VCIP135 is also involved in p97/p37-
assisted membrane fusion events. Wang et al. (2004)
have reported that VCIP135 shows deubiquitinating ac-tivity and that p97/p47-dependent cisternal regrowth is
inhibited by the addition of a ubiquitin mutant (Ile-44 to
Ala, Ub[I44A]), which is unable to bind to p47. We there-
fore tested the effect of the ubiquitin mutant in the p97/
p37 pathway (Figure 7F). The addition of Ub(I44A) during
Golgi disassembly inhibited the cisternal regrowth
caused by p97/p47, but it did not affect the regrowth
caused by p97/p37.
The results of the Golgi reassembly assay with salt-
washed mitotic Golgi fragments are presented in Fig-
ure 7G. When salt-washed membranes were incubated
with p97/p37 and p115, no cisternal regrowth was ob-
served. When VCIP135 together with p97/p37 and p115
were added, cisternal regrowth was observed. Thus,
VCIP135 is an essential cofactor for p97/p37-dependent
cisternal regrowth. Wang et al. (2004) also showed that
neither VCIP135(C218S) nor VCIP135(C218A), which
lack deubiquitinating activity, functioned in p97/p47-
dependent Golgi reassembly. We tested these VCIP135
mutants in p97/p37-mediated activity (Figure 7G). There
was no difference between VCIP135wt and mutants in
p97/p37-dependent Golgi cisternal regrowth, although
neither of the VCIP135 mutants functioned in p97/p47-
dependent cisternal regrowth. These results clearly indi-
cate that p97/p37-assisted membrane fusion requires
VCIP135, but not its deubiquitinating activity.
Developmental Cell
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in p37-Depleted Cells
(A) Either mock-treated or p37 siRNA1-
treated HeLa cells were transfected with
ts045-VSV-G-GFP to measure the rate of
membrane transport. ts045-VSV-G-GFP was
stained with antibodies to GFP and observed
by confocal microscopy. Representative im-
ages of cells for the 0, 20, and 60 min time
points are shown to compare the transport
of ts045-VSV-G-GFP in mock- and p37-
depleted cells. The scale bar is 10 mm.
(B) Three sets of cells were counted: one in
which ts045-VSV-G-GFP remained at the ER
network only; a second in which it was local-
ized to the Golgi apparatus, but not to the
plasma membrane; and a third in which it
was transported to the plasma membranes.
We counted 417–501 cells at each time point
in either mock-treated or p37-depleted cells,
and the percentages of cells in each set are
shown.
(C) The effect of p37 on ERAD was clarified by
investigating the turnover of DF508CFTR in
either mock- or p37 siRNA1-treated HeLa
cells. As a positive control, MG132 (50 mM,
Calbiochem), a proteasome inhibitor, was
added instead of siRNA treatment. The re-
maining amounts of DF508CFTR in the cells
were analyzed by western blotting with anti-
CFTR monoclonal antibodies (insets). The
western blotting results were quantified by
using the NIH image, and the data for differ-
ent time points were normalized relative to
100% for the 0 time point. Means6 SD (n = 3).The p97/p37 Pathway Requires the SNARE GS15
in Golgi Reassembly
Muller et al. (2002) reported that NSF/SNAPs-dependent
Golgi reassembly does not require the ATPase activity
of NSF, since NSF/SNAPs has already dissociated the
SNARE complexes during Golgi disassembly. To explore
whether p97/p37 utilizes SNAREs primed by NSF/SNAPs
during Golgi disassembly or whether it can dissociate
SNARE complexes directly, we performed the in vitro
Golgi disassembly in the presence of N-ethylmaleimide
(NEM). In NEM-treated mitotic Golgi fragments, NEM in-
activates endogenous NSF and prevents NSF/SNAPs-
mediated SNARE dissociation. Using NSF-inactivated
membranes, we tested the membrane fusion activity of
p97/p37, as presented in Figure 8A. The untreated mi-
totic Golgi fragments were incubated with p97/NSF
ATP-hydrolysis-deficient mutants (p97[E305Q,E578Q]
or NSF[E329Q]), together with their respective cofactors.
Cisternal regrowth was observed in NSF(E329Q)/SNAPs
and p97wt/p37, but not in p97(E305Q,E578Q)/p37. When
NEM-treated membranes were used, p97wt/p37 still
caused cisternal regrowth, although NSF(E329Q)/SNAPs
lost its membrane fusion activity. Hence, p97/p37 doesnot utilize SNAREs primed by NSF/SNAPs during Golgi
disassembly; i.e., the p97/p37 pathway dissociates
SNARE complexes during Golgi reassembly without
the assistance of NSF/SNAPs.
The p97/p47 pathway utilizes syntaxin5 as a SNARE
(Rabouille et al., 1998). What SNAREs are involved in
the p97/p37 pathway? As shown in Figure 8B, the addi-
tion of either anti-syntaxin5 antibodies or recombinant
syntaxin5 lacking the transmembrane domain (a domi-
nant-negative form of syntaxin5, syn5DTM) had no ef-
fect on p97/p37-dependent cisternal regrowth, although
both the antibodies and the dominant-negative syn-
taxin5 inhibited p97/p47-dependent cisternal regrowth.
These results indicate that syntaxin5 is not involved in
p97/p37-dependent Golgi reassembly. We next tested
polyclonal antibodies raised against several known
SNAREs (Gos28, Bet1, membrin, sec22b, GS15, and
Ykt6), and we found that the addition of anti-GS15 anti-
bodies inhibited p97/p37-dependent cisternal regrowth
(Figure 8C). This inhibition was rescued by quenching
the antibodies with a GS15 fragment. The addition of re-
combinant GS15 lacking the transmembrane domain
(GS15DTM) also showed a significant inhibitory effect.
p97/p37 Is Required for Golgi and ER Biogenesis
811These results strongly suggest that GS15 is involved in
p97/p37-dependent Golgi reassembly.
In order to confirm these results biochemically, we
performed immunoprecipitation experiments with p37-
saturated Golgi membranes, as shown in Figures 8D
and 8E. GS15 and p37 were coimmunoprecipitated, in-
dicating that p37 is part of a GS15-containing complex.
Is the p97/p37/GS15-containing complex dissociated
by p97-mediated ATP hydrolysis? We incubated salt-
washed Golgi membranes together with His-p97 and
His-p37. The isolated membranes were solubilized and
used for immunoprecipitation with anti-GS15 antibodies
and protein A beads. The beads were then incubated
with VCIP135 in the presence of nucleotides. The results
are presented in Figure 8F. The beads contained p97
and p37 (lane 1), which was consistent with the results
shown in Figures 8D and 8E. When the beads were incu-
bated together with VCIP135 in the presence of ATP,
p97 and p37 were dissociated from the beads (lane 2).
However, when the beads were incubated together
with VCIP135 in the presence of AMP-PNP or ADP,
p97 and p37 still remained on the beads (lanes 3 and
4). Upon incubation in the presence of ATP, but without
VCIP135, the p97/p37/GS15-containing complex was
not dissociated (lane 5). Considering that the p97/p37
pathway can prime SNAREs (see Figure 8A and its re-
lated text in Results), these results probably show that
p97/p37 dissociates the SNARE complex by ATP hydro-
lysis with the assistance of VCIP135. VCIP135 bound to
the beads in both the presence and the absence of p97
and p37 (lanes 1 and 6), and the amount remaining on
the beads was slightly increased by incubation in the
presence of AMP-PNP (lane 3).
The p97/p37/GS15-containing complex was also sep-
arated by SDS-PAGE, followed by silver staining. In ad-
dition to the bands of p97, p37, GS15, and immunoglob-
ulin, we observed several bands of 20–35 kDa (data not
shown), which might be other SNAREs or SNARE-like
proteins involved in p97/p37-assisted fusion. We are
now purifying the complex on a large scale for protein
microsequencing.
Discussion
In our previous work (Uchiyama et al., 2003), we reported
that the p97/p47 pathway was less critical for Golgi main-
tenance during interphase compared to its reassembly
at the end of mitosis. Since p97 localizes to the cyto-
plasm as well as the nucleus during interphase, we rea-
soned that p97 might have another adaptor protein for
the maintenance of organelles in interphase. In this
study, we searched for p97-binding proteins by yeast
two-hybrid screening, and we have identified an adaptor
protein, p37. p37 localizes to the cytoplasm as well as the
nucleus, and it forms a complex with p97 in the cytosol.
Our p37-knockdown experiments with siRNA revealed
the important roles of p37 in the biogenesis of the Golgi
and ER. Injection of anti-p37 antibodies into cells at dif-
ferent cell cycle stages also shows that p37 plays an im-
portant role in Golgi and ER maintenance during inter-
phase as well as in their reassembly at the end of
mitosis. In an in vitro Golgi reassembly assay, the p97/
p37 complex displays membrane fusion activity. How-
ever, the p97/p37 pathway has a number of importantdifferences from the p97/p47 pathway (Table S1): (1) Un-
like the p97/p47 pathway, the p97/p37 pathway requires
p115 and GM130, a tethering protein and its binding part-
ner, respectively. (2) p37 does not bind ubiquitin, while
p47 binds monoubiquitin. (3) The p97/p37 pathway re-
quires VCIP135, but not its deubiquitinating activity. (4)
The p97/p37 pathway utilizes GS15 and other SNARE
proteins, but not syntaxin5.
It has been reported that p115 and GM130 form a com-
plex and function as a tethering system in the NSF-
dependent membrane fusion pathway (Nakamura et al.,
1997). Here, we also find that the p97/p37 pathway,
unlike the p97/p47 pathway, requires the p115-GM130
tethering system. This specific requirement for a p115-
GM130 tethering complex poses an interesting question
regarding the control of the p97/p37 pathway during the
cell cycle. Golgi disassembly-reassembly during mitosis
requires the blocking of membrane fusion at early mito-
sis and its unblocking at late mitosis (Warren, 1993). At
early mitosis, GM130 is phosphorylated, resulting in
the disruption of the p115-GM130 tethering complex
and subsequent mitotic inhibition of the NSF pathway
(Lowe et al., 1998). The activity of NSF/SNAP-mediated
SNARE priming is, however, maintained through mitosis
(Muller et al., 2002). In the case of the p97/p47 pathway,
p47 is also phosphorylated at early mitosis, which pre-
vents the binding of p97/p47 to Golgi membranes and
causes subsequent inhibition of p97/p47-assisted
membrane fusion (Uchiyama et al., 2003). Thus, in con-
trast to the NSF pathway, the p97/p47-assisted fusion
machinery per se is mitotically blocked.
This leads to the question as to how p97/p37-assisted
membrane fusion is blocked during early mitosis. Con-
sidering that p97/p37 requires the p115-GM130 tether-
ing complex, one possible explanation could be the
disruption of the tethering complex by the mitotic phos-
phorylation of GM130, similar to the NSF pathway. How-
ever, several recent reports have raised concerns re-
garding the requirement for p115-GM130 tethering in
trafficking. Vasile et al. (2003) have reported from the
analysis of the temperature-sensitive conditional-lethal
mutant IdlG that detectable levels (<5% of control) of
GM130 were not always necessary for normal Golgi mor-
phology. Linstedt and coworkers performed p115 siRNA
knockdowns coupled with overexpression of a p115
mutant unable to bind GM130, and they observed that
the p115 mutant could support normal Golgi structure
(Puthenveedu and Linstedt, 2004). Shorter and Warren
(1999) and our group (Uchiyama et al., 2003) showed
that p97 was dissociated from mitotic Golgi membranes.
Hence, it is likely that the p97/p37 complex is also disso-
ciated from mitotic Golgi membranes in a manner similar
to the p97/p47 complex, and that the p97/p37 fusion ma-
chinery per se is also mitotically blocked. Indeed, if the
activity of p97/p37 is intact through mitosis, similar to
what occurs with NSF/SNAPs, then SNAREs could be
primed during Golgi disassembly, and the p97 hydrolysis
mutant could then cause cisternal regrowth from NEM-
untreated mitotic Golgi fragments. However, very little
cisternal regrowth occurs with this p97 mutant (Fig-
ure 8A), supporting the notion that the activity of p97/
p37 is inhibited during Golgi disassembly.
An important difference between p37 and p47 is the
absence in p37 of a defined N-terminal UBA domain
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(A) Mitotic Golgi membranes were incubated with the indicated components at 37C for 60 min. Cytosol (w10 mg/ml) was prepared from rat
brain. Antibodies to p37 and p47 were polyclonal and affinity purified. The membranes were fixed and processed, and the percentage of mem-
brane in cisterna was determined. Mean6 SD (n = 4); 0% represents the buffer (20.7% in cisternal membranes), and 100% represents the cytosol
(44.8% in cisternal membranes).
(B) Mitotic Golgi membranes were incubated with the indicated components: p97 (50 mg/ml), p47 (20 mg/ml), p37 (19 mg/ml), p115 (30 mg/ml).
Mean 6 SD (n = 4); 0% represents the buffer (22.5% in cisternal membranes), and 100% represents p97/p47 alone (46.0% in cisternal
membranes).
(C) p97 (50 mg/ml), p115 (30 mg/ml), and several doses of p37 (0, 4.8, 9.5, 19, 38 mg/ml) were incubated with mitotic membranes. Mean6 SD (n = 6);
0% represents p37/p97 = 0 (22.5% in cisternal membranes), and 100% represents p37/p97 = 0.5 (49.3% in cisternal membranes). An asterisk
indicates a significant difference at p < 0.05 compared with the other points (Bonferroni method).
(D) Either anti-p115 or anti-GM130 antibodies were added to the indicated reassembly reactions as in (B). Mean6 SD (n = 4); 0% represents the
buffer (23.2% in cisternal membranes), and 100% represents p97/p37 + p115 (49.1% in cisternal membranes).
(E) Anti-VCIP135 antibodies were added to mitotic Golgi membranes together with the p97/p37 complex and p115 as in (B). Mean 6 SD (n = 4);
0% represents the buffer (24.8% in cisternal membranes), and 100% represents p97/p37 + p115 (48.5% in cisternal membranes).
(F) Golgi membranes were fragmented in the absence or presence of 40 mM exogenous ubiquitin (Ubwt) or the ubiquitin mutant (Ub[I44A]),
followed by incubation with the indicated components as in (B). Mean 6 SD (n = 4); 0% represents the buffer in the absence of exogenous
Ub (26.2% in cisternal membranes), and 100% represents p97/p37 + p115 in the absence of exogenous Ub (51.2% in cisternal membranes).
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813(Figure 1A), which, in p47, has been shown to bind mono-
ubiquitin, but not polyubiquitin, in the presence of p97
(Meyer et al., 2002). Furthermore, a p47 mutant lacking
the UBA domain showed less membrane fusion activity
in vitro (Meyer et al., 2002). The addition of a ubiquitin
mutant (Ub[I44A]) that cannot bind to p47 during Golgi
disassembly inhibited p97/p47-dependent Golgi reas-
sembly in vitro (Wang et al., 2004). VCIP135 mutants
lacking deubiquitinating activity did not function in the
p97/p47 pathway (Wang et al., 2004). Together, these re-
sults indicate that the p97/p47 pathway requires ubiqui-
tylation-deubiquitination of as yet unknown factors. In
contrast, no evidence was found to suggest the involve-
ment of ubiquitin in the p97/p37 pathway. Our biochem-
ical binding experiments reveal that p37 does not bind
ubiquitin in either the absence or presence of p97 (Fig-
ure 2E). The addition of a ubiquitin mutant (I44A) during
Golgi disassembly had no effect on p97/p37-dependent
Golgi reassembly in vitro (Figure 7F). VCIP135 mutants
(C218A and C218S) lacking deubiquitinating activity
functioned in the p97/p37 pathway (Figure 7G). Consid-
ering these results, it is unlikely that the p97/p37 pathway
requires ubiquitin for Golgi reassembly. What is the bio-
logical significance of the different requirement for ubiq-
uitin in the two p97-mediated pathways? The p97/p47
pathway appears specialized for the reassembly of or-
ganelles at the end of mitosis (Uchiyama et al., 2003).
Ubiquitylation is observed more widely during mitosis,
and the requirement for ubiquitin in the p97/p47 pathway
may contribute to its tight regulation during the cell cycle.
Although a small amount of p47 is observed in the cyto-
plasm at interphase, it does not function in the mainte-
nance of organelles (Uchiyama et al., 2003). A p47 mutant
lacking its nuclear localization signals is microinjected
into the cytoplasm of interphase cells to increase the
amount of cytoplasmic p47, but we cannot observe any
obvious morphological changes in the Golgi or ER
(K.U. and H.K., unpublished data). These observations
can be explained by the requirement for ubiquitin in the
p97/p47 pathway.
VCIP135 is reported to act as a deubiquitinating en-
zyme in p97/p47-dependent Golgi reassembly (Wang
et al., 2004), while it was originally identified as a p97/
p47 complex-interacting protein (Uchiyama et al.,
2002). In this study, we find that VCIP135 is required
for the dissociation of the p97/p37/GS15-containing
complex via p97-catalyzed ATP hydrolysis (Figure 8F,
lanes 2 and 5). As p37 and p47 have very similar amino
acid sequences, including their two p97 binding sites
(Figure 1A), it is plausible that VCIP135 can also work
as a p97/p37 complex-interacting protein and partici-
pate in the dissociation of the SNARE complex. These
findings suggest that the function of VCIP135 in the
priming of the SNARE complex is unlikely to require its
deubiqutinating activity. VCIP135 therefore seems to
work in two distinct ways: one via its deubiquitinating
activity; the other in a ubiquitin-independent manner,
perhaps as a p97/p37 (or p47) complex-interacting
protein.In our previous works and in this study, we have
shown that p97 uses two distinct adaptors for its mem-
brane fusion function: p47 is specialized for the reas-
sembly of organelles at the end of mitosis; p37 is for or-
ganelle maintenance during interphase as well as for
their reassembly during mitosis. Why are the two dis-
tinct p97 pathways required during the cell cycle? This
leads to another question as to what mechanistic differ-
ences exist between the reassembly and maintenance
of organelles. To answer these questions, much remains
to be done to clarify the molecular mechanisms of the
two p97 pathways.
Experimental Procedures
Proteins and Antibodies
p97, p47, Ufd1, Npl4, SVIP, syn5DTM, p115, and Ub-GST were pre-
pared as reported (Kondo et al., 1997; Meyer et al., 2000; Nagahama
et al., 2003; Rabouille et al., 1995a, 1998; Wang et al., 2004). Poly-
clonal antibodies to p47, p97, VCIP135, and syntaxin5 were pre-
pared as described (Kondo et al., 1997; Rabouille et al., 1998;
Uchiyama et al., 2002, 2003), and polyclonal antibodies to GS15
and p115 were raised against His-GS15DTM and His-p115(651–
961). Monoclonal anti-PDI antibodies and polyclonal anti-GM130
antibodies were gifts from Dr. Vaux (Oxford University, UK) and
Dr. Nakamura (Kanazawa University, Japan), respectively. Monoclo-
nal antibodies to p97, His tag, GM130, mannosidase II, and CFTR
were purchased from Progen, Qiagen, BD Transduction, Covance,
and Upstate, respectively.
Identification and cDNA Cloning of p37
The ORF of mouse p97 was subcloned into the yeast expression
vector pGBKT7. The plasmid was transformed into yeast strain
AH109, and a yeast two-hybrid screen was carried out essentially
according to the manufacturer’s protocol by using a GAL4 DNA ac-
tivation domain fusion library in pACT2 (Mouse Brain MATCH-
MAKER cDNA Library, Clontech). A total of 1 3 106 colonies were
screened, and 234 colonies were positive. One of them encoded
p37, a protein similar to p47. Its full cDNA sequence (AK012822)
was identified by an EST database search. The clone containing
the full cDNA sequence of p37 was isolated from a mouse embryo
cDNA library (Clontech) by PCR (primers: 50-TGAGGGCCGCAAG
CGGG-30, 50-CAGAATAACAGGAAAACCAG-30). This clone was se-
quenced, and a start codon was confirmed: it had a stop codon
immediately upstream of the start codon. The ORF of p37 was subcl-
oned into pQE30 by using BamHI and KpnI sites. Recombinant p37
was expressed in E. coli and was purified with Ni beads, followed by
further purification with superdex 200 and mono Q columns (Phar-
macia). His-tagged p37 was used to raise rabbit anti-p37 polyclonal
antibodies. The resulting antibody was confirmed not to crossreact
with p47.
Biochemical Experiments
Competition experiments with GST-p97 and binding experiments
with purified p97 and His-p37 were performed in buffer A (20 mM
HEPES, 1 mM MgCl2, 1 mM ATP, 1 mM DTT, 5% glycerol [pH 7.4])
containing 0.15 M KCl, 5 g/l trypsin inhibitor, and 0.1% Triton X-
100. To clarify the distribution of p37, rat brain cytosol was fraction-
ated by superose 6 (Pharmacia) in buffer A containing 0.15 M KCl.
The binding experiments with Ub-GST were performed in buffer A
containing 0.15 M KCl, 5 g/l trypsin inhibitor, and 0.5% Triton X-100.
For immunoprecipitation experiments with rat brain cytosol, the
cytosol (70 mg total protein) was mixed with affinity-purified anti-
p37 antibodies in buffer A containing 0.25 M KCl and 0.1% Triton
X-100. p37 and its binding proteins were precipitated by proteinG
beads.(G) 1 M KCl-washed or unwashed mitotic Golgi membranes was incubated with several components or their combinations: p97 (50 mg/ml), p47
(20 mg/ml), p37 (19 mg/ml), p115 (40 mg/ml), VCIP135wt (18 mg/ml), VCIP135(C218A) (18 mg/ml), VCIP135(C218S) (18 mg/ml). Mean 6 SD (n = 4);
0% represents the buffer (20.1% in cisternal membranes), and 100% represents non-salt-washed membranes with p97/p37 + p115 (49.0% in
cisternal membranes).
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(A) Golgi membranes were fragmented in the absence or presence of 2.5 mM NEM, followed by incubation with the indicated components: p97
(50 mg/ml), p97(E305Q,E578Q) (50 mg/ml), p37 (19 mg/ml), p115 (30 mg/ml), NSF(E329Q) (100 mg/ml), a-SNAP (25 mg/ml), b-SNAP (25 mg/ml).
Mean 6 SD (n = 4); 0% represents the buffer in the absence of NEM (23.8% in cisternal membranes), and 100% represents p97wt/p37 +
p115 in the absence of NEM (49.7% in cisternal membranes).
(B) Either an anti-syntaxin5 antibody or syntaxin5 without TM (syn5DTM, a dominant-negative form) was added to the indicated reassembly re-
actions: p97/p37 (50 mg p97/ml), p97/p47 (50 mg p97/ml), syn5DTM (150 mg/ml). Mean6 SD (n = 4); 0% represents the buffer (25.7% in cisternal
membranes), and 100% represents p97/p37 alone (52.0% in cisternal membranes).
(C) Either an anti-GS15 antibody or GS15 without TM (GS15DTM, a dominant-negative form) was added to the indicated reassembly reactions:
p97/p37 (50 mg p97/ml), p97/p47 (50 mg p97/ml), GS15DTM (320 mg/ml). Mean 6 SD (n = 4); 0% represents the buffer (23.4% in cisternal mem-
branes), and 100% represents p97/p37 alone (49.8% in cisternal membranes).
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KCl-washed Golgi membranes (120 mg) were first incubated with
His-p37 (15 mg) on ice for 1 hr. The isolated membranes were solubi-
lized in 100 ml buffer B (20 mM HEPES, 0.2 M KCl, 1 mM DTT, 1 mg/ml
BSA [pH 7.4]) containing 10% glycerol and 2% CHAPS and were
mixed with antibodies.
p97/p37/GS15-containing complexes were isolated and immobi-
lized as follows. 1 M KCl-washed Golgi membranes (360 mg) were in-
cubated with His-p97 (40 mg) and His-p37 (10 mg). The isolated mem-
branes were solubilized in 100 ml buffer B containing 1 mM MgCl2,
10% glycerol, and 2% CHAPS and were mixed with anti-GS15 poly-
clonal antibodies (15 mg) and protein G beads to prepare the beads
of p97/p37/GS15-containing complexes. After washing with buffer B
containing 1 mM MgCl2, 20% glycerol, and 0.1% Triton X-100, the
beads were incubated together with His-VCIP135 (10 mg) in the pres-
ence of the indicated nucleotides (10 mM) in a total volume of 200 ml
at 4C for 3 hr.
Knockdown of p37 by siRNA
p37 was targeted with independent siRNAs (B-Bridge International):
50-CAGUUUAGAUGAUGGAGAA-30 (p37 siRNA1), 50-CUCCAGAAGA
GGAGGAUAA-30 (p37 siRNA2), 50-ACUUGGAAGCCUUACACCU-30
(p37 siRNA3), 50-CUUUAUUCUUGUGACUUCA-30(p37 siRNA4). p37
siRNA1 and p37 siRNA2 were used for HeLa cells, and p37 siRNA3
and p37 siRNA4 were used for CHO-K1 cells. Each 10 nM siRNA du-
plex was transfected by using lipofectamin RNAimax (Invitrogen),
unless otherwise stated.
Injection of Antibodies and siRNA Duplexes into Cells
Either an affinity-purified antibody (w20 g/l) or random IgG (20 g/l)
was injected together with the injection marker Cy3-BSA (w1 g/l).
When injecting into interphase cells, the cells were incubated for
4 hr after the injection and were then fixed. The cells that entered mi-
tosis were removed every 1.5–2 hr during the incubation in order to
confirm that the remaining cells had never passed through mitosis.
In the case of injection into mitotic cells, cells were roughly synchro-
nized. Briefly, cells were cultured for 12 hr in the presence of aphidi-
colin (NRK cells, 0.5 mg/l; CHO-K1 cells, 0.25 mg/l). After washing
out aphidicolin, they were cultured for an additional 4 hr and then
injected.
The EM observation of injected cells was performed as described
previously (Uchiyama et al., 2002, 2003). Cells were grown on a cov-
erslip on which a square area ofw1 mm 3 1 mm was outlined by a
diamond pen. All cells within the area were injected and used for the
EM observation.
For the EM study of siRNA-treated cells, each siRNA duplex (20
mM) was injected three times at intervals of 24 hr into the cytoplasm
of the cells within the area. Uninjected cells within the area were com-
pletely removed after every injection by an injection needle by using
fluorescence of coinjected Cy3 as a marker. The cells were incubated
for an additional 24 hr after the third injection and were then fixed.
For observation of ER structures, we used a stable CHO-K1 cell
line expressing GFP-tagged HSP47, an ER protein (Uchiyama
et al., 2002). ER structures were observed in living cells, without fix-
ation, by using confocal microscopy.
VSV-G Transport Assay and DF508CFTR Degradation Assay
Each mock-treated or p37 siRNA-treated HeLa cell was transfected
with ts045-VSV-G-GFP. The p37 siRNA1 duplex was used for the de-
pletion of p37. Cells were first incubated for 2 hr at 37C and then for
15 hr at 39.5C. Before a temperature shift from 39.5C to 32C, cy-
cloheximide (100 mg/ml) was added to each dish, and cells were in-
cubated at 4C for 30 min. After 0, 10, 20, 30, 45, 60, and 90 min at
32C, cells were fixed with paraformaldehyde, permeabilized withTriton X-100, stained with monoclonal antibodies to GFP, and ob-
served by confocal microscopy.
HeLa cells were transfected with a humanDF508CFTR expression
vector (pFLAG-CMV-5A) 8 hr after mock or p37 siRNA treatment. p37
siRNA1 was used for the depletion of p37. Cells were incubated for
40 hr after transfection, and then cycloheximide (20 mg/ml) was
added into the culture medium. After incubation for the indicated
time, cells were harvested and used to investigate DF508CFTR turn-
over. To increase the expression level of DF508CFTR, cells were
incubated with 5 mM sodium butyrate for 16 hr before analysis.
In Vitro Golgi Reassembly Assay
The in vitro Golgi reassembly assay was performed as reported pre-
viously (Shorter and Warren, 1999). All proteins added in this assay
were prepared as recombinant proteins from E. coli. The length of
cisternae was measured by an intersection method (Rabouille
et al., 1995b).
Supplemental Data
Supplemental Data include the depletion of p37 by p37 siRNA du-
plexes, the mapping of p37 for the binding to Golgi membranes,
the interaction of p37 with SNAREs, and the comparison between
the p97/p37 and p97/p47 pathways and are available at http://
www.developmentalcell.com/cgi/content/full/11/6/803/DC1/.
Acknowledgments
We would like to thank C. Rabouille and N. Nakamura for their kind
and helpful advice; M. Lindman for her kind assistance with the
EM work; and S. Watanabe and H. Maekawa for their kind assistance
with the yeast two-hybrid screening. We give special thanks to
P. Luzio and the late K. Maruyama for their encouragement. M.P.
is a student of the Vikki Graduate School in Bioscience. E.J. is
funded by Helsinki University and the Academy of Finland. X.Z.
and P.F. are funded by the Wellcome Trust. This work is supported
by a grant to H.K. from the Ministry of Education, Culture, Sports,
Science and Technology of Japan.
Received: June 30, 2005
Revised: September 8, 2006
Accepted: October 19, 2006
Published: December 4, 2006
References
Dalal, S., Rosser, M.F., Cyr, D.M., and Hanson, P.I. (2004). Distinct
roles for the AAA ATPases NSF and p97 in the secretory pathway.
Mol. Biol. Cell 15, 637–648.
Kondo, H., Rabouille, C., Newman, R., Levine, T.P., Pappin, D., Free-
mont, P., and Warren, G. (1997). p47 is a cofactor for p97-mediated
membrane fusion. Nature 388, 75–78.
Lowe, M., Rabouille, C., Nakamura, N., Watson, R., Jackman, M.,
Jamsa, E., Rahman, D., Pappin, D.J., and Warren, G. (1998). Cdc2 ki-
nase directly phosphorylates the cis-Golgi matrix protein GM130
and is required for Golgi fragmentation in mitosis. Cell 94, 783–793.
Lucocq, J.M., Berger, E.G., and Warren, G. (1989). Mitotic Golgi frag-
ments in HeLa cells and their role in the reassembly pathway. J. Cell
Biol. 109, 463–474.
Meyer, H.H., Shorter, J.G., Seemann, J., Pappin, D., and Warren, G.
(2000). A complex of mammalian ufd1 and npl4 links the AAA-
ATPase, p97, to ubiquitin and nuclear transport pathways. EMBO
J. 19, 2181–2192.(D and E) Salt-washed Golgi membranes were first incubated in the presence of His-tagged p37. The isolated membranes were solubilized and
mixed with either (D) anti-GS15 polyclonal or (E) anti-His monoclonal antibodies. The immunoprecipitates were fractionated by SDS-PAGE. The
blots were probed with the following antibodies: anti-His monoclonal and anti-GS15 polyclonal antibodies in (D); anti-p37 and anti-GS15 poly-
clonal antibodies in (E).
(F) Salt-washed Golgi membranes were incubated with His-p97 and His-p37. The isolated membranes were solubilized and mixed with anti-
GS15 antibodies and protein G beads. The resulting beads were incubated with or without His-VCIP135 in the presence of the indicated nucle-
otide. Proteins bound to the beads were fractionated by SDS-PAGE, followed by western blotting. The blots were probed with antibodies to p97,
GS15, and His tag.
Developmental Cell
816Meyer, H.H., Wang, Y., and Warren, G. (2002). Direct binding of ubiq-
uitin conjugates by the mammalian p97 adaptor complexes, p47 and
Ufd1-Npl4. EMBO J. 21, 5645–5652.
Muller, J.M., Shorter, J., Newman, R., Deinhardt, K., Sagiv, Y., Elazar,
Z., Warren, G., and Shima, D.T. (2002). Sequential SNARE disassem-
bly and GATE-16-GOS-28 complex assembly mediated by distinct
NSF activities drives Golgi membrane fusion. J. Cell Biol. 157,
1161–1173.
Nagahama, M., Suzuki, M., Hamada, Y., Hatsuzawa, K., Tani, K.,
Yamamoto, A., and Tagaya, M. (2003). SVIP is a novel VCP/p97-
interacting protein whose expression causes cell vacuolation. Mol.
Biol. Cell 14, 262–273.
Nakamura, N., Lowe, M., Levine, T.P., Rabouille, C., and Warren, G.
(1997). The vesicle docking protein p115 binds GM130, a cis-Golgi
matrix protein, in a mitotically regulated manner. Cell 89, 445–455.
Puthenveedu, M.A., and Linstedt, A.D. (2004). Gene replacement re-
veals that p115/SNARE interactions are essential for Golgi biogene-
sis. Proc. Natl. Acad. Sci. USA 101, 1253–1256.
Rabouille, C., Levine, T.P., Peters, J.M., and Warren, G. (1995a).
An NSF-like ATPase, p97, and NSF mediate cisternal regrowth
from mitotic Golgi fragments. Cell 82, 905–914.
Rabouille, C., Misteli, T., Watson, R., and Warren, G. (1995b). Reas-
sembly of Golgi stacks from mitotic Golgi fragments in a cell-free
system. J. Cell Biol. 129, 605–618.
Rabouille, C., Kondo, H., Newman, R., Hui, N., Freemont, P., and
Warren, G. (1998). Syntaxin 5 is a common component of the NSF-
and p97-mediated reassembly pathways of Golgi cisternae from mi-
totic Golgi fragments in vitro. Cell 92, 603–610.
Shorter, J., and Warren, G. (1999). A role for the vesicle tethering pro-
tein, p115, in the post-mitotic stacking of reassembling Golgi cister-
nae in a cell-free system. J. Cell Biol. 146, 57–70.
Uchiyama, K., Jokitalo, E., Kano, F., Murata, M., Zhang, X., Canas,
B., Newman, R., Rabouille, C., Pappin, D., Freemont, P., and Kondo,
H. (2002). VCIP135, a novel essential factor for p97/p47-mediated
membrane fusion, is required for Golgi and ER assembly in vivo.
J. Cell Biol. 159, 855–866.
Uchiyama, K., Jokitalo, E., Lindman, M., Jackman, M., Kano, F.,
Murata, M., Zhang, X., and Kondo, H. (2003). The localization and
phosphorylation of p47 are important for Golgi disassembly-assem-
bly during the cell cycle. J. Cell Biol. 161, 1067–1079.
Vasile, E., Perez, T., Nakamura, N., and Krieger, M. (2003). Structural
integrity of the Golgi is temperature sensitive in conditional-lethal
mutants with no detectable GM130. Traffic 4, 254–272.
Wang, Y., Satoh, A., Warren, G., and Meyer, H.H. (2004). VCIP135
acts as a deubiquitinating enzyme during p97-p47-mediated reas-
sembly of mitotic Golgi fragments. J. Cell Biol. 164, 973–978.
Warren, G. (1993). Membrane partitioning during cell division. Annu.
Rev. Biochem. 62, 323–348.
Ye, Y., Meyer, H.H., and Rapoport, T.A. (2001). The AAA ATPase
Cdc48/p97 and its partners transport proteins from the ER into the
cytosol. Nature 414, 652–656.
Accession Numbers
The p37 nucleotide sequence is available in the DNA Data Bank of
Japan database under accession code AB120715.
